Prof. S. Odes, Department of Gastroenterology and Hepatology, Soroka Medical Center, P. O. Box 151, Beer Sheva 84101, Israel.
E-mail: [email protected]

Read the full text

About

PDF

Tools

Share a link

Email
Wechat
Bluesky

Abstract

Aliment Pharmacol Ther 31, 735–744

Summary

Background Forecasting clinical and economic outcomes in ulcerative colitis (UC) and Crohn’s disease (CD) patients is complex, but necessary.

Aims To determine: the frequency of treatment-classified clinical states; the probability of transition between states; and the economic outcomes.

Methods Newly diagnosed UC and CD patients, allocated into seven clinical states by medical and surgical treatments recorded in serial 3-month cycles, underwent Markov analysis.

Results Over 10 years, 630 UC and 318 CD patients had 22,823 and 11 871 cycles. The most frequent clinical outcomes were medical/surgical remission (medication-free) and mild disease (on 5-aminosalicylates, antibiotics, topical corticosteroids), comprising 28% and 62% of UC cycles and 24% and 51% of CD cycles respectively. The probability of drug-response in patients receiving systemic corticosteroids/immunomodulators was 0.74 in UC, 0.66 in CD. Both diseases had similar likelihood of persistent drug-dependency or drug-refractoriness. Surgery was more probable in CD, 0.20, than UC, 0.08. In terms of economic outcomes, surgery was costlier in UC per cycle, but the outlay over 10 years was greater in CD. Drug-refractory UC and CD cases engendered high costs in the cohort.

Conclusions Most patients on 5-aminosalicylates, corticosteroids and immunomodulators had favourable clinical and economic outcomes over 10 years. Drug-refractory and surgical patients exhibited greater long-term expenses.

Supporting Information

References

1 Loftus EV Jr, Schoenfeld P, Sandborn WJ. The epidemiology and natural history of Crohn’s disease in population-based patient cohorts from North America: a systematic review. Aliment Pharmacol Ther 2002; 16: 51–60.
10.1046/j.1365-2036.2002.01140.x
PubMed Web of Science® Google Scholar
2 Odes S, Vardi H, Friger M, et al. Cost-analysis and cost-determinants in a European inflammatory bowel disease inception cohort with 10 years follow-up evaluation. Gastroenterology 2006; 131: 719–28.
10.1053/j.gastro.2006.05.052
PubMed Web of Science® Google Scholar
3 Wolters FL, Van Zeijl G, Wessels F, et al. Internet-based data inclusion in a European epidemiological follow-up study of IBD patients: a description of methods used. World J Gastroenterol 2005; 11: 7152–8.
10.3748/wjg.v11.i45.7152
PubMed Web of Science® Google Scholar
4 Munkholm P, Langholz E, Davidsen M, Binder V. Disease activity courses in a regional cohort of Crohn’s disease patients. Scand J Gastroenterol 1995; 30: 699–706.
10.3109/00365529509096316
CAS PubMed Web of Science® Google Scholar
5 Silverstein MD, Loftus EV, Sandborn WJ, et al. Clinical course and costs of care for Crohn’s disease: Markov model analysis of a population-based cohort. Gastroenterology 1999; 117: 49–57.
10.1016/S0016-5085(99)70549-4
CAS PubMed Web of Science® Google Scholar
6 Wolters F, Joling C, Russell MG, et al. Treatment inferred disease severity in Crohn’s disease: evidence for a European gradient of disease course. Scand J Gastroenterol 2007; 42: 333–44.
10.1080/00365520600930750
PubMed Web of Science® Google Scholar
7 Shivananda S, Lennard-Jones J, Logan R, et al. Incidence of inflammatory bowel disease across Europe: is there a difference between north and south? Results of the European Collaborative Study on Inflammatory Bowel Disease (EC-IBD) Gut 1996; 39: 690–7.
10.1136/gut.39.5.690
CAS PubMed Web of Science® Google Scholar
8 Briggs A, Claxton K, Sculpher M. Decision Modelling for Health Economic Evaluation. Oxford: Oxford University Press, 2006.
10.1093/oso/9780198526629.001.0001
Google Scholar
9 Drummond M, McGuire A, eds. Economic Evaluation in Health Care. Oxford: Oxford University Press, 2001.
10.1093/oso/9780192631770.001.0001
Google Scholar
10 Drummond MF, O’Brien BJ, Stoddart GL, Torrance GW. Methods for the Economic Evaluation of Health Care Programmes. Oxford: Oxford University Press, 2nd ed 1997.
Google Scholar
11 Spiegel BM, Targownik LE, Kanwal F, et al. The quality of published health economic analyses in digestive diseases: a systematic review and quantitative appraisal. Gastroenterology 2004; 127: 403–11.
10.1053/j.gastro.2004.04.020
PubMed Web of Science® Google Scholar
12 Siegel JE, Weinstein MC, Torrance GW. Reporting cost-effectiveness studies and results. In: MR Gold, JA Siegel, LB Russell, et al. Cost-Effectiveness in Health and Medicine. New York: Oxford University Press, 1996: 276–303.
Google Scholar
13 Cox NJ. Stata module to generate Markov probabilities. ResearchGate Scientific Network. https://www.researchgate.net/publication/4921961 .
Google Scholar
14 Matthews DE, Farewell VT. Using and Understanding Medical Statistics. Basel: Karger, 2nd ed 2007.
10.1159/isbn.978-3-318-01406-8
Google Scholar
15 Lennard-Jones JE, Shivananda S. Clinical uniformity of inflammatory bowel disease a presentation and during the first year of disease in the north and south of Europe. EC-IBD Study Group. Eur J Gastroenterol Hepatol 1997; 9: 353–9.
10.1097/00042737-199704000-00007
CAS PubMed Web of Science® Google Scholar
16 Sonnenberg FA, Beck JR. Markov models in medical decision making. A practical guide. Med Decis Making 1993; 13: 322–38.
10.1177/0272989X9301300409
CAS PubMed Web of Science® Google Scholar
17 Craig BA, Sendi PP. Estimation of the transition matrix of a discrete-time markov chain. Health Econ 2002; 11: 33–42.
10.1002/hec.654
PubMed Web of Science® Google Scholar
18 Odes S, Friger M, Vardi H, et al. Effect of phenotype on health care costs in Crohn’s disease: a European study using the Montreal classification. J Crohn’s Colitis 2007; 1: 87–96.
10.1016/j.crohns.2007.08.004
Web of Science® Google Scholar
19 Langholz E, Munkholm P, Davidsen M, Binder V. Course of ulcerative colitis: analysis of changes in disease activity over years. Gastroenterology 1994; 107: 3–11.
10.1016/0016-5085(94)90054-X
CAS PubMed Web of Science® Google Scholar
20 Hoie O, Wolters FL, Riis L, et al. Low colectomy rates in ulcerative colitis in an unselected European cohort followed for 10 years. Gastroenterology 2007; 132: 507–15.
10.1053/j.gastro.2006.11.015
PubMed Web of Science® Google Scholar
21 Jess T, Riis L, Vind I, et al. Changes in clinical characteristics, course, and prognosis of inflammatory bowel disease during the last 5 decades: a population-based study from Copenhagen, Denmark. Inflamm Bowel Dis 2007; 13: 481–9.
10.1002/ibd.20036
PubMed Web of Science® Google Scholar
22 Wolters FL, Russel MG, Sijbrandij J, et al. Crohn’s disease: increased mortality 10 years after diagnosis in a Europe-wide population based cohort. Gut 2006; 55: 510–8.
10.1136/gut.2005.072793
CAS PubMed Web of Science® Google Scholar
23 Hoie O, Schouten LJ, Wolters FL, et al. Ulcerative colitis: no rise in mortality in a European-wide population-based cohort 10 years after diagnosis. Gut 2007; 56: 497–503.
10.1136/gut.2006.101519
CAS PubMed Web of Science® Google Scholar
24 Bodger K, Kikuchi T, Hughes D. Cost-effectiveness of biological therapy for Crohn’s disease: Markov cohort analyses incorporating United Kingdom patient-level cost data. Aliment Pharmacol Ther 2009; 30: 265–74.
10.1111/j.1365-2036.2009.04033.x
CAS PubMed Web of Science® Google Scholar
25 Bassi A, Dodd S, Williamson P, Bodger K. Cost of illness of inflammatory bowel disease in the UK: a single centre retrospective study. Gut 2004; 53: 1471–8.
10.1136/gut.2004.041616
CAS PubMed Web of Science® Google Scholar
26 Jaisson-Hot I, Flourié B, Descos L, Colin C. Management for severe Crohn’s disease: a lifetime cost-utility analysis. Int J Technol Assess Health Care 2004; 20: 274–9.
10.1017/S0266462304001084
PubMed Web of Science® Google Scholar
27 Marshall K, Blackhouse G, Goeree R, et al. Clinical and Economic Assessment: Infliximab for the Treatment of Crohn’s Disease: Technology Overview. 8. Ottawa: Canadian Coordinating Office for Health Technology Assessment (CCOHTA), 2008.
Google Scholar
28 Travis SP, Stange EF, for the European Crohn’s and Colitis Organisation (ECCO). European evidence based consensus on the diagnosis and management of Crohn’s disease: current management. Gut 2006; 55(suppl 1): i1–58.
Web of Science® Google Scholar
29 Travis SPL, Stange EF, Lemann M, et al. European evidence-based consensus on the management of ulcerative colitis: current management. J Crohn’s Colitis 2008; 2: 24–62.
10.1016/j.crohns.2007.11.002
CAS PubMed Web of Science® Google Scholar

Citing Literature

Volume31, Issue7

April 2010

Pages 735-744

Clinical and economic outcomes in a population-based European cohort of 948 ulcerative colitis and Crohn’s disease patients by Markov analysis

Abstract

Summary

Supporting Information

References

Citing Literature

References

Information

About Wiley Online Library

Help & Support

Opportunities

Connect with Wiley

Clinical and economic outcomes in a population-based European cohort of 948 ulcerative colitis and Crohn’s disease patients by Markov analysis

Abstract

Summary

Supporting Information

References

Citing Literature

References

Related

Information